1	Characterization of genomic regulation profiles in human mitral valve whole								
2	tissue to annotate genetic risk loci for mitral valve prolapse								
3									
4	Sergiy Kyryachenko ¹ , PhD [*] , Adrien Georges ¹ , PhD [*] , Mengyao Yu ¹ , PhD [*] , Takiy Barrandou ¹ ,								
5	PhD, Patrick Bruneval ¹ , MD, PhD, Tony Rubio ^{2,3} , MSc, Judith Gronwald ^{2,3} , Hassina Baraki ^{3,4} ,								
6	MD, Ingo Kutschka ^{3,4} , MD, Russell. A Norris ^{5,6} , PhD, Niels Voigt ^{2,3} , MD, Nabila Bouatia-Naji ¹ ,								
7	PhD								
8									
9	1. Université de Paris, PARCC, Inserm, Paris, France								
10	2. Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Germany								
11	3. DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Germany								
12	4. Department of Thoracic and Cardiovascular Surgery, University Medical Center, Göttingen,								
13	Germany								
14	5. Department of Regenerative Medicine and Cell Biology, Medical University of South								
15	Carolina, Charleston, SC, USA;								
16	6. Department of Medicine, Medical University of South Carolina, Charleston, SC, USA								
17	* Drs Kyryachenko, Georges, and Yu contributed equally to this work as joint first authors.								
18									
19	Short title: Regulatory profiles of mitral valves								
20									

- 21 Corresponding author: Nabila Bouatia-Naji, email: nabila.bouatia-naji@inserm.fr, address: Paris
- 22 Cardiovascular Research Center Inserm U970, 56 rue Leblanc, F-75015 Paris, France

23

- 24 **Total word count:** 8,141
- 25 Subject terms: Valvular Heart Disease, Functional Genomics, Genetics, Etiology

27 ABSTRACT

Rationale: Mitral valve prolapse (MVP) is a common valve disease that leads to mitral insufficiency, heart failure and sudden death. The identification of risk loci provided insight into its genetic architecture, although the causal variants and target genes need to be fully characterized.

Objective: To establish the chromatin accessibility profiles and gene regulation specificities of
 human mitral valve and identify functional variants and target genes at MVP loci.

Methods and Results: We mapped the open chromatin accessible regions in nuclei from 11 34 35 human mitral valves by an assay for transposase-accessible chromatin with high-throughput 36 sequencing (ATAC-Seq). Compared to the heart tissue and cardiac fibroblasts, we found that mitral valve-specific ATAC-Seq peaks were enriched near genes involved in extracellular matrix 37 38 organization, chondrocyte differentiation, and connective tissue development. The most enriched motif in mitral valve-specific open chromatin peaks was for the nuclear factor of activated T 39 cells (NFATC) family of transcription factors, involved in valve endocardial and interstitial cells 40 formation. We also found that MVP-associated variants ($p < 10^{-5}$) observed in the current MVP 41 42 GWAS were significantly enriched (p<0.05) in mitral valve open chromatin peaks. Integration of 43 the ATAC-Seq data with GWAS loci, extensive functional annotation, and gene reporter assay revealed plausible causal variants at two risk loci: rs6723013 at the IGFBP5/TNS1 locus and 44 rs2641440 at the SMG6/SRR locus. Circular chromosome conformation capture followed by 45 46 high-throughput sequencing provided evidence for several target genes, including SRR, HIC1, and DPH1 at the SMG6/SRR locus and further supported TNS1 as the most likely target gene on 47 Chr2. 48

49 **Conclusions**: Here we describe unprecedented genome-wide open chromatin profiles from 50 human mitral valves that indicates specific gene regulation profiles, compared to the heart. We 51 also report *in vitro* functional evidence for potential causal variants and target genes at MVP risk 52 loci involving established and new biological mechanisms relevant to mitral valve disease.

53 **Key Words:** Mitral valve prolapse, functional annotation at GWAS loci, ATAC-Seq, 4C-Seq.

55 **Introduction**

Mitral valve presents specific cellular and tissue organization, compared to the heart and the 56 57 vessels. The mature mitral valve is mainly composed of valvular interstitial cells (VICs), and is 58 covered by a layer of valvular endothelial cells (VECs). These cells communicate via paracrine signaling, and altered or damaged signaling within the VECs can lead to pathological changes in 59 underlying VICs.^{1,2,3} VICs are relatively quiescent non-contractile fibroblast-like cells that 60 contribute to homeostasis of extracellular matrix (ECM).⁴ During valve development or under 61 62 mechanical stress, VICs change phenotype and become activated myofibroblast-like cells that produce matrix metalloproteinases and inflammatory cytokines, which increase matrix 63 production and remodel the ECM.^{5,6,7} Under excessive constant stress or TGF-β stimulation, this 64 65 process leads to myxomatous degeneration of the valve causing mitral valve prolapse (MVP), a 66 common valve disease. MVP affects nearly one in 40 adults and predisposes to mitral regurgitation, arrhythmias, and sudden cardiac death.^{8,9,10} Mitral regurgitation is the second most 67 68 frequent indication for valve surgery, where valve reparation and replacement represent an important public health cost.¹¹ The causes of MVP development and evolution are still poorly 69 70 understood.

In a previous genome-wide association study (GWAS) for MVP, we identified six validated genetic risk loci, all located in intergenic or intronic noncoding regions.¹² Associated variants are potentially located near regulatory elements that may be involved in the adjustment of target genes expression, specific to mitral valve. In the context of GWAS association signals, typically including large number of highly correlated genetic variants, the identification of potential causal variants and target genes requires the annotation of loci with epigenomic data generated from disease-relevant tissues.^{13,14} However, the most commonly used techniques, such as DNase-seq or histone-ChIP, require relatively high amount of cells, which excludes many tissues, including
heart valve, from such analyses. On the other hand, expression quantitative trait loci (eQTL) in
disease-relevant tissues are widely used to narrow down causal variants and potential target
genes at GWAS loci,¹⁵ but such datasets are not available for the mitral valve.

82 Here we aimed to fill in the existing gap in functional annotation datasets for human mitral valve 83 using the assay for transposase accessible chromatin using high-throughput sequencing (ATAC-Seq) approach, a genomic technique that provides a high-resolution map of open chromatin from 84 samples with low cell content, as is the case of mitral valve tissue. Using this genomic annotation 85 technique, we provide valuable information about active gene expression and main regulatory 86 elements within human mitral valve cells. As a complementary approach, and in the absence of 87 88 eQTL datasets for mitral valve, we performed circular chromatin conformation capture analyzed by high-throughput sequencing (4C-Seq) to provide evidence for physical proximity between 89 MVP-associated variants and promoters as an indication of possible regulatory event between 90 genetic variants and target genes.^{16,17} Finally, we provide two successful examples of the 91 92 application of the genomic annotation, which we have generated, combined with chromatin architecture and gene reporter enhancer assay in vitro to propose candidate genetic variants for 93 causality and their potential target genes at MVP GWAS loci. 94

96 Materials and Methods

97 Sample acquisition and patient consent

Mitral valve tissue was acquired at University Medical Center Göttingen, Georg-August
University of Göttingen, Germany with written and informed consent through Institutional
Review Board (IRB) protocol Nº 4/11/18. Freshly obtained mitral valve tissue from 11 patients
who underwent mitral valve replacement surgery (Supplementary Table S1) was snap frozen in
liquid nitrogen and stored at -80°C.

103

104 Cell culture

Primary adult human dermal fibroblasts (HDF) (ATCC, Manassas, VA) and human cardiac fibroblasts (HCF) (Cell Applications, San Diego, CA) cells were purchased at passage 2 from LGC Standards, France and Tebu-bio, France respectively, and cultured in 5% CO2 in a 37°C incubator. HDF were maintained in fibroblast basal medium (ATCC, Manassas, VA) with fibroblast growth kit-low serum (ATCC, Manassas, VA), and HCF were maintained in HCF growth medium (Cell Applications, San Diego, CA) according to the manufactures' instructions.

111

112 Isolation of nuclei from frozen mitral valves for ATAC-Seq

Frozen mitral valve tissues were mechanically dissociated in liquid nitrogen using mortar and pestle. Grinded tissue was transferred into 15 ml Falcon tubes containing 5 ml of cold homogenization buffer (HB): 10 mM Tris-HCl pH 7.6, 10 mM NaCl, 3 mM MgCl2, 0.1% NP40, 0.1% Tween-20, 0.01% Digitonin, 250mM Sucrose, and EDTA-free complete protease inhibitors (Roche, Pleasanton, CA). The homogenate was filtered through 400 µm cell strainer

(pluriStrainer, Leipzig, Germany). Then, the isolation of nuclei was performed as described¹⁸ 118 with modifications. Specifically, after Dounce homogenization, the tissue homogenate was 119 pelleted at 500g for 10 minutes at 4°C. Tissue homogenate (700-800 µl) was transferred to a 14 120 121 ml round bottom tube (Greiner Bio-One, Frickenhausen, Germany) and mixed with an equal volume of 50% iodixanol in HB to obtain a final 25% iodixanol. 1200 µl of 30% iodixanol in HB 122 was layered underneath the 25% mixture, and then 1200 µl of 40% iodixanol in HB was layered 123 124 below the 30% iodixanol. Nuclei were enriched at 3,000g for 20 minutes at 4°C in a swinging-125 bucket centrifuge. Nuclei that accumulated at the 30%/40% interface were collected into a 1.5 ml Lo-Bind Eppendorf tube, stained with Trypan Blue, and manually counted under microscope. 126

127

128 Library preparation for ATAC-Seq

HDF and HCF cells at passage 5 were trypsinized, counted using a Nucleocounter NC-100 129 (Chemometec, Allerod, Denmark), and 50,000 cells were collected for each experiment. Isolated 130 from mitral valves nuclei were transferred into a 1.5 ml Lo-Bind Eppendorf tube containing 1 ml 131 ATAC-resuspension buffer with 0.1% Tween-20 and pelleted at 500 g for 10 minutes at 4°C.¹⁸ 132 Depending on the number of nuclei (30,000-100,000) that were obtain, the transposition reaction 133 134 was scaled up or down. The transposition reaction was performed as described in the Omni-ATAC protocol.¹⁸ Then, the transposition reaction was purified with MinElute PCR Purification 135 Kit (QIAGEN, Hilden, Germany). Library amplification was performed as described 136 previously.¹⁹ Amplified DNA was purified using Agencourt AMPure XP beads (Beckman 137 Coulter, Brea, CA), according to manufacturer's instructions. 138

140 Sequencing of ATAC-Seq libraries and peak calling

141 ATAC-seq libraries were sequenced using 42 paired-end sequencing cycles on an Illumina NextSeq500 system at the high throughput sequencing core facility of Institute for Integrative 142 143 Biology of the Cell (CNRS, France). Reads were demultiplexed using bcl2fastq2-2.18.12, and 31 to 95 million reads (fragments) were obtained per sample. Adapter sequences were trimmed 144 using CutAdapt v1.15. For heart samples from ENCODE, raw reads from ATAC-Seq 145 146 experiments on human heart left ventricle (ENCSR117PYB, ENCSR851EBF) and human right atrium auricular region (ENCSR062SVK) were downloaded from ENCODE webserver. Read 147 length was adjusted to 42bp using Cutadapt. Further analyses were performed on the Galaxy 148 webserver.²⁰ Reads were mapped on GRCh38 (hg38) genome using Bowtie2 v2.3.4.3 with 149 default settings, except reads could be paired at up to 2kb distance. Aligned reads were filtered 150 151 using BAM filter v0.5.9, keeping only mapped, properly paired reads, and removing secondary alignment and PCR duplicate reads as well as blacklisted regions.²¹ ATAC peaks were called 152 using MACS2 callpeak v2.1.1.20160309.6 with default settings. Binary read density files 153 154 (bigwig) were created using bamCoverage v3.3.0.0.0, normalized on hg38 genome. BEDTool 155 AnnotateBed v2.29.0 was used to compare peak files.

156

157 Analysis of chromatin accessibility profiles

To perform sample correlation and principal component analysis, a common list of enriched regions was generated using bedtools multiple intersect (Galaxy Version 2.29.0) in "cluster" mode, and average read coverage on these regions was computed using deepTools multiBamsummary (Galaxy Version 3.3.2.0.0). deepTools plotCoverage and plotPCA functions were used to calculate Pearson correlation between samples and Principal Component Analysis,

respectively. Global peak annotation was performed using ChIPSeeker v1.22.0.²² We used 163 Diffbind (Galaxy Version 2.10.0) to detect differentially accessible regions between heart and 164 mitral valve samples.²³ clusterProfiler v3.14.0 was used to annotate genes at proximity of 165 ATAC-Seq peaks and identify enriched gene ontology terms.²⁴ Identified GOBP terms were 166 clustered using REVIGO webserver (http://revigo.irb.hr/), with "medium" settings.²⁵ We 167 analyzed ATAC-seq peaks for enrichment in putative TF binding motifs using MEME-ChIP tool 168 on MEME webserver (http://meme-suite.org/)²⁶ set with HOCOMOCO Human v11 motif 169 database. We used Integrated Genome Browser (IGB) to visualize read density profiles and peak 170 positions in the context of human genome.²⁷ 171

172

173 **Prioritization of functional SNPs using annotation tools**

Analysis of SNP enrichment among ATAC-Seq peaks was performed using GREGOR.²⁸ The 174 sentinel SNPs from loci associated with p-value $< 10^{-5}$ were used as reference for MVP-175 associated SNPs. We included in the analysis SNPs in high LD ($r^2 < 0.7$) in European samples 176 from 1000 Genomes. To use homogenous peak sets and mitigate the difference in signal-to-noise 177 ratio between samples, 500bp windows centered on peak summits were used for this analysis. 178 179 Next, to prioritize the most possible functional SNPs at each of the risk loci, we annotated each SNP with overlapping mitral valve ATAC-Seq peaks (narrowpeak from MCAS2 output + 100bp 180 on each side), presence of overlapping H3K27ac histone mark from heart left ventricle, heart 181 right atrium, ascending aorta or primary fibroblasts (peaks from ENCODE datasets: 182 ENCFF052BXS, ENCFF172RFM, ENCFF208DZK, ENCFF222SST, ENCFF222WPT, 183 ENCFF283CXG, ENCFF332RJQ, ENCFF385NNX, ENCFF401EEA, ENCFF491RWJ, 184

185 ENCFF617BNF, ENCFF670ZUM, ENCFF686LUV, ENCFF824SPW, ENCFF946SRJ,
 186 ENCFF964UAX, and ENCFF984MJS) and RegulomeDB score.²⁹

187

188 Conditional analyses using GWAS data at *IGFBP5/TNS1* and *SMG6/SRR* loci

Using genotype data from our previous study¹², we performed an updated association analysis on 189 chromosome 2 and chromosome 17 using newly imputed SNPs obtained from the HRC³⁰ as 190 imputation reference panel through Michigan imputation server³¹. We used results from our 191 GWAS meta-analysis as described previously.¹² We used the GCTA-COJO function to perform 192 conditional analyses to identify secondary or causal signals on loci.³² The COJO analysis used 193 the MVP-France case control study as reference panel to calculate linkage disequilibrium (LD) 194 between SNPs. To avoid collinearity issues, SNPs in high LD $(r^2>0.9)$ with the tested SNP were 195 excluded before analyses. 196

197

198 Circular chromatin conformation capture followed by high-throughput sequencing (4C199 Seq)

The 4C template was prepared as previously described.³³ In summary, 10 million of HDF were fixed in 2% formaldehyde, and then the cells were lysed to isolate nuclei. The chromatin was digested *in situ* with the four-base cutter MboI (New England Biolabs, Ipswich, MA) for 16 hours at 37°C followed by *in situ* ligation with T4 ligase (Thermo Fisher Scientific, Waltham, MA). Chromatin was decross-linked at 65°C overnight, followed by a second digestion with the four-base cutter NlaIII (New England Biolabs, Ipswich, MA). Digested fragments were diluted and self-ligated using T4 ligase to generate circular chromatin conformation capture (4C) library. 207 The efficiency of each digestion and ligation step was validated on agarose gels. Viewpoints were selected on the basis of the MVP susceptibility loci found in the GWAS.¹² To study the 208 chromatin interactions of MVP-associated susceptibility loci with 4C, primers (Supplementary 209 Table S2) were designed for each viewpoint as described previously.³³ 4C libraries were 210 sequenced using single-end 75bp reads on an Illumina NextSeq500 system at the high 211 throughput sequencing core facility of Institute for Integrative Biology of the Cell (CNRS, 212 213 France). The raw sequencing reads were demultiplexed on the basis of viewpoint-specific primer 214 sequences. Reads were trimmed of sequences preceding MboI (GATC) site on 5' end and following NlaIII site (CATG) on 3'end (if site was present in the read) using Cutadapt (Galaxy 215 Version 1.16.6) on Galaxy webserver.²⁰ Trimmed reads were mapped on GRCH37 (hg19, for 216 r3Cseq package) and GRCH38 (hg38, for visualization) genomes using Bowtie2 v2.3.4.3 with 217 218 default settings. Unmapped reads and secondary alignments were filtered out using Filter bam v0.5.9. Kept reads were processed using the R-package r3Cseq to detect significant 219 interactions.³⁴ All 4C-seq images were generated using default parameters of the pipeline. 220

221

222 Vector construction, cell transfection, and dual-luciferase reporter gene assay

Details about primers and vector construction are presented in the supplementary appendix and in Supplementary Table S3. The constructed vector that contained the test SNP (90 ng for 96well plate) and internal control plasmid pRL-TK (Promega, Madison, WI) (10 ng for 96-well plate) were co-transfected into HDF. The cells were plated at 4000 cells/well into a 96-well white plate 24 hours before transfection. The cells were transfected with a TransfeX transfection reagent (ATCC, Manassas, VA) according to the manufacturer's instructions. Dual-luciferase reporter gene assays were performed after 48h post-transfection. Mithras LB 940 instrument

230	(Berthold Technologies, Bad Wildbad, Germany) was used to measure the luciferase activity
231	with the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). All experiments were
232	performed according to the instructions recommended by the manufacturer. The luciferase
233	activity data were obtained from at least eight replicate wells, and the experiments were repeated
234	3 times. Two-tailed Student's t-test was used to compare if the difference was significant and the
235	significance threshold was set at $P < 0.05$.
236	
237	

238

239 **Results**

240 Mapping the chromatin accessibility profiles of human mitral valve tissue

We sought to get insight into the regulatory features of valve tissue by determining the chromatin 241 242 accessibility profiles of surgically removed mitral valves using ATAC-Seq. We obtained between 55 and 95 million paired-end reads from the generated ATAC-Seq libraries of isolated 243 244 nuclei from 11 valves. Peak calling ranged between 7,165 and 74,837 peaks, with five samples 245 having at least 30,000 peaks (Figure 1A). We calculated Spearman correlation between samples 246 to assess the variability in our experiment. We identified two main clusters: cluster A formed by 247 the five samples where we obtained at least 30,000 peaks, and Cluster B formed by the six 248 remaining samples, although these were relatively less correlated, indicating more inter-sample 249 heterogeneity (Figure 1B). The visual examination of read density profiles showed that samples 250 from Cluster A represented optimal quality ATAC-Seq data (Figure 1C). We therefore selected Cluster A samples (MV1671, MV1700, MV1772, MV1830, and MV1846) for further analyses. 251

Comparison of chromatin accessibility profiles between mitral valve, heart tissues, and fibroblast cells

254 To determine whether mitral valve ATAC-Seq allows the identification of valve specific 255 regulatory elements, we compared our data to primary cultures of fibroblasts and heart tissue. 256 We determined chromatin accessibility in human dermal fibroblasts (HDF, two samples) and 257 human cardiac fibroblasts (HCF, one sample), and reanalyzed through our pipeline ATAC-Seq 258 experiments on heart left ventricle (Heart LV, two samples) and heart right atrium auricular 259 region (Heart RAAR, one sample) from ENCODE. We obtained more than 130,000 peaks in all 260 three fibroblasts samples, and 20,000 to 40,000 peaks from heart tissue (Figure 2A). We then 261 annotated the genomic localization of ATAC-Seq peaks obtained in all samples. A large 262 proportion of peaks observed in mitral valves were located in promoter regions (25 to 50%, 263 according to samples, Figure 2B). Overall, 75 to 80% of peaks were located in the promoter or 264 transcribed regions of genes, corresponding to usual localization of regulatory elements in the human genome identified by ATAC-Seq.³⁵ 265

We calculated Spearman correlation between all samples and identified three main clusters corresponding to mitral valve, heart samples, and primary cultured fibroblasts (Figure 2C). Heart samples from ENCODE clustered closer to mitral valve than to primary fibroblasts. Similarly, principal component analyses showed that tissue samples clustered together and separately from fibroblasts along the first principal component, which explains about 90% of the observed variance, whereas heart and mitral valve samples were separated by second principal component, accounting for about 5% of the total variance (Figure 2D).

274 Chromatin accessibility profiles present regulatory features specific to mitral valve

275 To detect mitral valve-specific regulatory elements, we compared mitral valve samples to heart tissue samples. We identified 9758 peaks specifically enriched in the heart or mitral valve 276 (FDR≤0.05, Figure 3A). To assess the global gene function controlled by these putative 277 regulatory regions, we considered genes for which the transcription starting site (TSS) was 278 279 located at 10kb or less distance from the enriched peaks (promoters or proximal regulatory 280 elements), and we performed their functional annotation using Gene Ontology Biological Process (GOBP) terms. Genes at proximity of heart-specific ATAC-Seq peaks present strong 281 enrichment for genes involved in heart contraction ($p=6\times10^{-19}$), muscle cell differentiation 282 $(p=3\times10^{-16})$, and other pathways related to heart function (Figure 3B, Supplementary Table 1 and 283 2). Mitral valve-specific ATAC-Seq peaks were strongly enriched at proximity of genes involved 284 in different biological pathways including ECM organization $(p=5\times10^{-15})$, chondrocyte 285 differentiation ($p=6\times10^{-11}$), and terms associated to connective tissue development (Figure 3C, 286 Supplementary Tables 3 and 4). We also note among top enriched terms those related to cell-cell 287 adhesion and communication (e.g actin filament organization and the ephrin receptor signaling 288 pathway) (Supplementary Tables 3 and 4). 289

Results of the enrichment analyses for transcription factor motifs also differ between heart and mitral valve. The most enriched motifs among heart-specific peaks were motifs for transcription factors involved in heart development and function^{36,37,38}, mainly the Kruppel-like factor (KLF) and myocyte enhancer factor-2 (MEF2) families (Figure 3D). In the mitral valve-specific peaks, the top enriched motif corresponds to transcription factors of the nuclear factor of activated T cells (NFATC) family (Figure 3E). 296

Mitral valve specific open chromatin peaks are enriched for MVP associated loci

297 Mitral valve ATAC-Seq data provide potential regulatory elements that may participate to the pathogenesis of MVP. To investigate further this idea, we tested the enrichment for associated 298 SNPs from existing MVP GWAS results among different ATAC-Seq datasets.¹² We used the 299 Genomic Regulatory Elements and GWAS Overlap algorithm (GREGOR)²⁸ that compares the 300 301 number of trait-associated SNPs overlapping predefined genomic regions (here, ATAC-Seq peaks) with randomized SNP matched by regions (1Mb window) and frequency. Figure 4A 302 shows that MVP-associated SNPs ($p < 10^{-5}$) were significantly enriched (p < 0.05) in ATAC-Seq 303 peaks from all mitral valve samples whereas significant enrichment was found for only one of 304 305 the other samples (Heart LV-2). Maximal enrichment was seen for MV1830, for which ATAC-Seq peaks overlapped over 4 times more MVP-associated SNPs than expected ($p=6\times10^{-6}$, Figure 306 4A). Comparatively, ATAC-Seq peaks from fibroblasts samples did not significantly overlap 307 with MVP-associated SNPs, despite the fact that most peaks from mitral valves were also 308 309 observed in fibroblast ATAC-Seq peaks.

310

311 Identification of potential causal variants at MVP-associated loci

Given the enrichment for regulatory elements near genes involved in myxomatous valve biology, we sought to use the mitral valve ATAC-Seq datasets to narrow down a list of potential causal SNPs at MVP-associated loci. We selected associated SNPs (p < 0.001) from the six loci reaching genome-wide significance in our previous study¹² and filtered for colocalization with mitral valve ATAC-Seq peaks (Table 1). Between three and 20 SNPs were identified at each locus, representing a list of potential causal SNPs. We annotated these SNPs using RegulomeDB scores from 1 (most likely to affect TF binding and expression of a target gene) to 6 (least likely), and for the presence of H3K27ac enhancer/promoter marks in heart tissue (left ventricle or right atrium), ascending aorta, and dermal fibroblasts (Table 1).

321 To assess the validity of our approach, we sought to confirm the potential of selected SNPs as 322 causal for MVP association. At the IGFBP5/TNS1 locus on Chr2, where we had observed the strongest association signal in the discovery GWAS meta-analysis,¹² only three SNPs overlapped 323 324 ATAC-Seq peaks, and among them rs6723013 had the most significant association. Rs6723013 325 directly overlapped an H3K27ac histone mark in the heart left ventricle tissue, indicating it may 326 be a part of an active enhancer region (Table 1). To further verify the regulatory effect of this 327 SNP, we cloned 696bp DNA surrounding rs6723013, containing either rs6723013 reference (T) or alternative allele (G), upstream of *firefly luciferase* gene in a reporter vector. We then 328 329 transfected these constructs in HDF, in which the region appeared to be active, and we measured 330 the expression of luciferase. Interestingly, we found that T allele of rs6723013 was associated with significantly higher expression levels of firefly luciferase (reporter gene) than the 331 332 alternative G allele of SNP rs6723013 (p=0.006), whereas the construct containing G allele did not differ significantly from a control construct containing 751bp DNA from an inactive region 333 334 (Figure 4B). These results show that rs6723013 genotype affects the regulatory properties of this enhancer and support it as a causal variant. In support of this, the conditional analysis on 335 rs6723013, caused the association signal to totally disappear and indicated that this variant to 336 337 totally drive the association at this locus (Supplementary Table S4, Figure 4C-D), (Figure 4D).

We applied the same strategy to the *SMG6/SRR* locus on Chr17, which is also known as a risk locus for other cardiovascular traits, such as aortic root size and coronary artery disease.^{39,40,41} Colocalization analysis showed that 21 SNPs directly overlap mitral valve ATAC-Seq peaks and

18 of these SNPs also overlap H3K27ac marks in at least one tissue, most of them in all the 341 342 tested tissues. Among these SNPs, rs2641440 was ranked by RegulomeDB as the most likely 343 regulatory SNP (RegulomeDB score=1f), and it belongs to a strongly active region in all assayed 344 tissues (Table 1). We also selected rs9899330 for in vitro tests, given its RegulomeDB high score 2b (Table 1), and low linkage disequilibrium with rs2641440 (r²=0.21, CEU 1000 genomes), 345 suggesting it may belong to a secondary association signal. We then tested the effect of 346 347 rs2641440 and rs9899330 genotypes on the regulatory activity of the surrounding region in HDF. 348 The vector with the alternative C allele for rs2641440 had significantly higher luciferase activity 349 compared with the construct containing the reference G allele (p=0.0017) (Supplementary Figure S1A). Both constructs that contained alternative or reference allele of rs9899330 significantly 350 enhanced the activity of luciferase compared with the control construct, but had no allelic effect 351 352 on the regulatory activity of surrounding region (Supplementary Figure S1B). Interestingly, 353 conditional analyses both on rs2641440 and rs9899330 at SMG6/SRR locus (Supplementary Table S4) caused a decrease of the association signal (Supplementary Figure S1C-F), supporting 354 355 the existence of two independent signals at this locus.

356

357 Identification of potential target genes at MVP-associated loci

To get further insight into the biology of MVP, we sought to determine potential target genes at each of the six confirmed MVP-associated loci¹². First, we examined potential causal SNPs (Table 1) for eQTL association with genes in any human tissue using the Genotype-Tissue Expression (GTEx) portal (Table 2). Then, we performed circular chromatin conformation capture (4C) followed by high-throughput sequencing (4C-Seq) in human dermal fibroblasts to verify the potential target genes. We selected one to four viewpoints at each locus focusing on 364 potentially functional SNPs according to the functional annotation, or at the closest genomic 365 regions where we could design primers. Then, we used r3Cseq package to determine fragments that were significantly enriched in the 4C-Seq library (Supplementary Figure S2-5). Genes were 366 367 considered as potential target genes if their promoter was present within 5kb of an enriched fragment or of a potentially functional SNP (Table 2). Neither eQTL nor 4C-seq analyses 368 showed statistically significant association with target genes at the IGFBP5/TNS1 MVP-369 370 associated locus (Supplementary Figure S2A, B, Table 2). At the Chr3 MVP-associated locus, 371 we found interactions between the viewpoint and the promoter region of LMCD1 gene 372 (Supplementary Figure S2C) and no evidence for long range regulation for the nearby CAV3, which is highly expressed in the heart, and rare mutations may cause long QT syndrome.^{42,43} Our 373 analyses also pointed out potential target genes at the Chr14, Chr21, and Chr22 MVP-associated 374 375 loci, and further studies should explore their role in the MVP disease (Table 2, Supplementary 376 Figure S3 and S5). On Chr17, variants at the SMG6/SRR locus had eQTL association with many potential target genes, including SMG6, SRR, TSR1, SGSM2, HIC1, and DPH1 (Table 2). 4C-seq 377 378 analyses from rs9899330 viewpoint showed significant interactions with promoters of HIC1 and DPH1, which are located upstream of SMG6. (Figure 5, Supplementary Figure S4D). 379 Interestingly, we detected numerous significant interactions between the selected viewpoints and 380 the open chromatin regions within SMG6/SRR locus (Figure 5, Supplementary Figure S4). In 381 382 particular, all viewpoints interacted with the same region containing strong enhancer signals close to a SMG6 alternative promoter. These results suggest that active regions at this locus 383 strongly interact together, and support the presence of multiple causal SNPs participating to the 384 associations targeting multiple genes at this locus. 385

387

388 **Discussion**

389 In this study, we used epigenomic approaches to unravel the regulatory profile of human mitral 390 valve tissue and leveraged this data to investigate functional variants and target genes at MVPassociated loci. We showed that mitral valves genome-wide open chromatin profiles are distinct 391 from those of the cardiac tissue and fibroblasts, and are enriched near genes that are highly 392 393 relevant and specific to the development of the valve and to the myxomatous process. 394 Combining *in vitro* enhancer activity and chromatin tri-dimensional architecture, we were able to 395 identify functional variants at the IGFBP5/TNS1 and SMG6/SRR loci and narrow down the list of target genes at several MVP confirmed loci. 396

397 Our data support that open chromatin mapping of diseased mitral valves provides a useful 398 resource on cell differentiation and regulation of the myxomatous process. We found that 399 ATAC-Seq peaks were highly enriched for genes relevant to valve biology and disease, such as 400 ECM and connective tissue development and cytoskeleton organization, including actin filament 401 and cell adhesion. Of particular interest are the open chromatin peaks near genes related to the 402 ephrin receptor signaling pathway, an important family of transmembrane tyrosine kinase 403 receptors that ensure short cell-cell communication. This pathway is involved in the regulation of 404 epithelial-to-mesenchymal transformation during heart valve morphogenesis, and Efnal knockout mice exhibit the thickening of both aortic and mitral valves.⁴⁴ Another relevant process 405 406 is chondrogenic differentiation, which is part of the valve myxomatous degeneration process of VICs.⁴⁵ We found the NFATC family of transcription factors to be the most enriched motif in 407 408 mitral valve-specific open chromatin regions. NFATC1, in particular, is known to be a key factor

in heart valve and VICs development and its regulation may play a role in myxomatous
degeneration.^{46,47,48} NFATC1 is also expressed in adult human pulmonary VECs, and VEGFinduced NFATC1 activation can participate in the valve maintenance by increasing proliferation
of VECs.⁴⁹ A study reported microarray gene expression to be increased for NFATC2 and
NFATC4 in myxomatous mitral valves compared to normal valves.⁵⁰ Our results encourage
future studies to understand the specific role of NFATCs in the establishment of MVP.

Our study shows that MVP-associated SNPs are significantly enriched among identified mitral valve open chromatin peaks, but not among regions accessible in dermal or cardiac fibroblasts. Despite the fibroblast-like phenotype of VICs and VECs, our results are in favor of open chromatin and active regulation in mitral valve tissue to significantly differ from the one observed in cultured fibroblasts derived from the skin or the heart.

Our approach to fine-map GWAS loci using chromatin accessibility data derived from mitral 420 valve tissue, combined with the visualization of long-range genomic interaction using 4C-Seq 421 422 method, allowed us to identify potential causal variants and to narrow down the list of target 423 genes at risk loci, especially on chromosomes 2 and 17. At the IGFBP5/TNS1 MVP-associated locus we identified rs6723013 as a functional enhancer in vitro and demonstrated regulatory 424 425 allelic effect. Presence of the minor T allele (T=0.24, frequency in TOPMed panel) can modulate 426 the expression of potential target genes by altering transcription factor binding onto DNA. 427 Several TFs, such as OVOL2 and NFE2L1, are predicted to bind more to the major G allele. 428 OVOL2 suppresses epithelial-to-mesenchymal transition and thus maintains epithelial lineages, 429 and NFE2L1 regulates expression of target genes in response to various stresses. Further studies are needed to explore their involvement in gene regulation by this enhancer region. Potential 430 431 target genes at this locus were IGFBP5, IGFBP2, and TNP1 that are located upstream from the

432 signal, and DIRC1 and TNS1 located downstream from the signal. According to the chromatin organization observed from our 4C-Seq data, IGFBP2, IGFBP5, and TNS1 were all part of the 433 same TAD, which argues for high probability of contact between these genes promoters and the 434 435 enhancer containing the functional variant. IGFBP2 and IGFBP5 are two members of the insulin growth factor binding protein family. Igfbp5 is expressed in the developing mouse heart,⁵¹ and 436 differentially expressed in VECs during postnatal ECM remodeling and leaflet morphogenesis in 437 P7 and P30 murine valves.⁵² However, we have previously shown the absence of atrioventricular 438 regurgitation properties in zebrafish knockdown experiments of *igfbp2* and *igfbp5* fish 439 orthologs.¹² In the same study, significant atrioventricular regurgitation was found in zebrafish 440 knockdown, and $Tns1^{-/-}$ mice exhibited myxomatous phenotype of mitral valves.¹² In light of 441 these elements, we conclude that TNS1 is the most plausible causal gene at the IGFBP5/TNS1 442 443 locus through a potential long-range gene regulation mechanism, similar to previously described genomic organizations.^{53,54} 444

The SMG6/SRR locus is an intriguing and genetically complex locus reported to be associated 445 with several cardiovascular traits, including coronary artery disease.^{40,41} Our updated association 446 analysis, using a more dense imputed set of variants, provides several hundreds of variants in 447 high LD to significantly associate with MVP at this locus. Filtering for the overlap with ATAC-448 449 Seq peaks in mitral valves and enhancer marks, prior to reporter assay experiments, provided 450 evidence for enhancer capacity in vitro for rs2641440, with the G allelic variant (G=0.64, 451 TOPMed) at risk for MVP. Nonetheless, the conditional analysis supported the presence of several secondary signals at this locus, and we cannot exclude additional functional effects from 452 the untested SNPs. The SMG6/SRR locus is located in a gene-rich region that contains 453 454 overlapping promoters. Our 4C-Seq showed that all fours viewpoints that we tested as potential 455 enhancers were located within open chromatin in mitral valves, suggesting synergic regulation of several nearby genes.⁵⁵ We have previously excluded *SMG6* and *SGSM2* candidacy for causality 456 at this locus as neither smg6 nor sgsm2 knockdown in zebrafish led to an abnormal cardiac 457 phenotype.¹² Our chromatin interaction results now highlight new potential target genes. 458 including HIC ZBTB transcriptional repressor 1 (HIC1), diphthamide biosynthesis 1 (DPH1), 459 and serine racemase (SRR) genes, all expressed in heart tissues.^{56,57,58} HIC1 is a partner of TCF-460 4, and this complex attenuates Wnt/β-catenin signaling, an important mechanism for heart valve 461 development and myxomatous degeneration.^{59,45} On the other hand, patients with mutations in 462 DPH1 present heart abnormalities, including ventricular septal defect and aortic stenosis.⁶⁰ 463 Finally, several associated variants are located at the promoter of SRR, which catalyzes the 464 synthesis of D-serine from L-serine, and among its related pathways is calcium signaling.⁶¹ 465

466

Our work presents several limitations. First, it is the absence of non-pathogenic valves as 467 controls, which limited direct comparison of the regulatory profiles between healthy and 468 469 myxomatous valves. Second, open chromatin profiles obtained from ATAC-seq methods provide indirect assessment of transcriptional activity. Direct assessment of transcription using RNA-Seq 470 471 would be useful to determine the specific regulatory features of mitral valves, although their poor 472 cellular content represents a technical challenge. Third, enhancer activity tested in vitro in 473 dermal fibroblasts may differ from *in vivo* native chromatin activity in VICs and VECs. Finally, 474 our results are conditioned by the limited resolution of the 4C-Seq experiments, which do not allow refinement at gene-rich loci as the SMG6/SGSM2. 475

In conclusion, we provide for the first time mitral valve genome-wide chromatin accessibility profiles and demonstrate that this valuable data source to substantially contribute to deciphering MVP etiology. We show that MVP-associated variants are significantly and specifically enriched in open chromatin of myxomatous valves. Using *in vitro* functional validation, in combination with long range chromatin interaction experiments, we provide evidence for causal SNPs at two MVP-associated loci and several target genes of high relevance to valve development and degenerative process.

484

485 ACKNOWLEDGMENTS

486 The authors thank Ines Müller and Stefanie Kestel for excellent technical assistance.

487

488 FUNDING SOURCES

489 This study was supported by a Ph.D. scholarship from the China Scholarship Council to MY, French 490 Agency of Research (ANR-16-CE17-0015-02) to NB-N. AG, SK and NB-N are supported by a European 491 Research Council grant (ERC-Stg-ROSALIND-716628). This work was supported by grants from the 492 Deutsche Forschungsgemeinschaft (DFG) to NV (VO 1568/3-1, IRTG1816, and SFB1002 493 project A13), from the Else-Kröner-Fresenius Foundation to NV (EKFS 2016 A20) and from the German Center for Cardiovascular Research to NV (DZHK GOE MD3 and SE181). This 494 495 work was supported in part by grants from the National Institutes of Health (GM103444 to RAN; R01HL131546, P20GM103444, and R01HL127692 to RAN; and American Heart Association 496 497 (19TPA34850095 to RAN, 17CSA33590067 to RAN).

498

499 **DISCLOSURES**

500 None

502 **REFERENCES**

- Huk DJ, Austin BF, Horne TE, Hinton RB, Ray WC, Heistad DD, Lincoln J. Valve endothelial cell-derived tgfbeta1 signaling promotes nuclear localization of sox9 in interstitial cells associated with attenuated calcification. *Arteriosclerosis, thrombosis, and vascular biology*.
 2016;36:328-338
- Menon V, Lincoln J. The genetic regulation of aortic valve development and calcific disease.
 Frontiers in cardiovascular medicine. 2018;5:162
- Shapero K, Wylie-Sears J, Levine RA, Mayer JE, Jr., Bischoff J. Reciprocal interactions between mitral valve endothelial and interstitial cells reduce endothelial-to-mesenchymal transition and myofibroblastic activation. *Journal of molecular and cellular cardiology*. 2015;80:175-185
- Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. *Annual review of physiology*. 2011;73:29-46
- 5. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of
 interstitial cell phenotype during remodeling of cardiac valves. *The Journal of heart valve disease*. 2004;13:841-847
- 517 6. Levine RA, Hagege AA, Judge DP, et al. Mitral valve disease--morphology and mechanisms.
 518 *Nature reviews. Cardiology.* 2015;12:689-710
- 519 7. Hjortnaes J, Camci-Unal G, Hutcheson JD, Jung SM, Schoen FJ, Kluin J, Aikawa E,
 520 Khademhosseini A. Directing valvular interstitial cell myofibroblast-like differentiation in a
 521 hybrid hydrogel platform. *Advanced healthcare materials*. 2015;4:121-130
- Nishimura RA, McGoon MD. Perspectives on mitral-valve prolapse. *The New England journal of medicine*. 1999;341:48-50
- Avierinos JF, Gersh BJ, Melton LJ, 3rd, Bailey KR, Shub C, Nishimura RA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic mitral valve prolapse in the community. *Circulation*. 2002;106:1355-1361
- 527 10. Spartalis M, Tzatzaki E, Spartalis E, Athanasiou A, Moris D, Damaskos C, Garmpis N, Voudris
 528 V. Mitral valve prolapse: An underestimated cause of sudden cardiac death-a current review of
 529 the literature. *Journal of thoracic disease*. 2017;9:5390-5398
- Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. *The Canadian journal of cardiology*. 2014;30:962-970
- 532 12. Dina C, Bouatia-Naji N, Tucker N, et al. Genetic association analyses highlight biological
 533 pathways underlying mitral valve prolapse. *Nature genetics*. 2015;47:1206-1211
- Bryois J, Garrett ME, Song L, et al. Evaluation of chromatin accessibility in prefrontal cortex of
 individuals with schizophrenia. *Nature communications*. 2018;9:3121
- Kyono Y, Kitzman JO, Parker SCJ. Genomic annotation of disease-associated variants reveals
 shared functional contexts. *Diabetologia*. 2019;62:735-743
- Fagny M, Paulson JN, Kuijjer ML, Sonawane AR, Chen CY, Lopes-Ramos CM, Glass K,
 Quackenbush J, Platig J. Exploring regulation in tissues with eqtl networks. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114:E7841-E7850
- 541 16. Simonis M, Klous P, Splinter E, Moshkin Y, Willemsen R, de Wit E, van Steensel B, de Laat W.
 542 Nuclear organization of active and inactive chromatin domains uncovered by chromosome
 543 conformation capture-on-chip (4c). *Nature genetics*. 2006;38:1348-1354
- Vermunt MW, Zhang D, Blobel GA. The interdependence of gene-regulatory elements and the 3d genome. *The Journal of cell biology*. 2019;218:12-26
- 546 18. Corces MR, Trevino AE, Hamilton EG, et al. An improved atac-seq protocol reduces background
 547 and enables interrogation of frozen tissues. *Nature methods*. 2017;14:959-962
- Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. Atac-seq: A method for assaying chromatin
 accessibility genome-wide. *Current protocols in molecular biology*. 2015;109:21 29 21-21 29 29

550 20. Afgan E, Baker D, Batut B, et al. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic acids research. 2018;46:W537-W544 551 552 21. Amemiya HM, Kundaje A, Boyle AP. The encode blacklist: Identification of problematic regions 553 of the genome. Scientific reports. 2019;9:9354 554 22. Yu G, Wang LG, He OY. Chipseeker: An r/bioconductor package for chip peak annotation, 555 comparison and visualization. Bioinformatics. 2015;31:2382-2383 556 23. Ross-Innes CS, Stark R, Teschendorff AE, et al. Differential oestrogen receptor binding is 557 associated with clinical outcome in breast cancer. Nature. 2012;481:389-393 558 24. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: An r package for comparing biological themes 559 among gene clusters. Omics : a journal of integrative biology. 2012;16:284-287 Supek F, Bosnjak M, Skunca N, Smuc T. Revigo summarizes and visualizes long lists of gene 560 25. 561 ontology terms. PloS one. 2011;6:e21800 562 26. Machanick P, Bailey TL. Meme-chip: Motif analysis of large DNA datasets. *Bioinformatics*. 2011;27:1696-1697 563 564 27. Freese NH, Norris DC, Loraine AE. Integrated genome browser: Visual analytics platform for 565 genomics. Bioinformatics. 2016;32:2089-2095 566 28. Schmidt EM, Zhang J, Zhou W, Chen J, Mohlke KL, Chen YE, Willer CJ. Gregor: Evaluating 567 global enrichment of trait-associated variants in epigenomic features using a systematic, datadriven approach. Bioinformatics. 2015:31:2601-2606 568 569 29. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using regulomedb. Genome research. 2012;22:1790-1797 570 571 30. Vergara C, Parker MM, Franco L, Cho MH, Valencia-Duarte AV, Beaty TH, Duggal P. 572 Genotype imputation performance of three reference panels using african ancestry individuals. 573 Human genetics. 2018;137:281-292 574 Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and methods. 31. 575 *Nature genetics.* 2016;48:1284-1287 576 Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-snp analysis of gwas 32. 577 summary statistics identifies additional variants influencing complex traits. *Nature genetics*. 578 2012;44:369-375, s361-363 579 Matelot M, Noordermeer D. Determination of high-resolution 3d chromatin organization using 33. 580 circular chromosome conformation capture (4c-seq). *Methods in molecular biology*. 581 2016:1480:223-241 582 34. Thongjuea S, Stadhouders R, Grosveld FG, Soler E, Lenhard B. R3cseq: An r/bioconductor 583 package for the discovery of long-range genomic interactions from chromosome conformation 584 capture and next-generation sequencing data. Nucleic acids research. 2013;41:e132 585 35. Sheffield NC, Furey TS. Identifying and characterizing regulatory sequences in the human genome with chromatin accessibility assays. Genes. 2012;3:651-670 586 Nemer M, Horb ME. The klf family of transcriptional regulators in cardiomyocyte proliferation 587 36. 588 and differentiation. Cell cycle. 2007;6:117-121 589 37. Kelsey L, Flenniken AM, Qu D, et al. Enu-induced mutation in the DNA-binding domain of klf3 590 reveals important roles for klf3 in cardiovascular development and function in mice. PLoS 591 genetics. 2013;9:e1003612 Desjardins CA, Nava FJ. The function of the mef2 family of transcription factors in cardiac 592 38. 593 development, cardiogenomics, and direct reprogramming. Journal of cardiovascular development 594 and disease. 2016;3 595 39. Vasan RS, Glazer NL, Felix JF, et al. Genetic variants associated with cardiac structure and 596 function: A meta-analysis and replication of genome-wide association data. Jama. 2009;302:168-597 178 598 40. Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new 599 susceptibility loci for coronary artery disease. Nature genetics. 2011;43:333-338

600 41. Wild PS, Felix JF, Schillert A, et al. Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. The Journal of clinical investigation. 601 602 2017;127:1798-1812 603 42. Tyan L, Foell JD, Vincent KP, et al. Long qt syndrome caveolin-3 mutations differentially modulate kv 4 and cav 1.2 channels to contribute to action potential prolongation. The Journal of 604 physiology. 2019;597:1531-1551 605 606 43. Wallace E, Howard L, Liu M, O'Brien T, Ward D, Shen S, Prendiville T. Long qt syndrome: 607 Genetics and future perspective. *Pediatric cardiology*. 2019;40:1419-1430 608 44. Frieden LA, Townsend TA, Vaught DB, Delaughter DM, Hwang Y, Barnett JV, Chen J. 609 Regulation of heart valve morphogenesis by eph receptor ligand, ephrin-a1. Developmental 610 dynamics : an official publication of the American Association of Anatomists. 2010;239:3226-611 3234 612 45. Fang M, Alfieri CM, Hulin A, Conway SJ, Yutzey KE. Loss of beta-catenin promotes chondrogenic differentiation of aortic valve interstitial cells. Arteriosclerosis, thrombosis, and 613 vascular biology. 2014;34:2601-2608 614 Wu B, Wang Y, Lui W, Langworthy M, Tompkins KL, Hatzopoulos AK, Baldwin HS, Zhou B. 615 46. 616 Nfatc1 coordinates valve endocardial cell lineage development required for heart valve formation. 617 *Circulation research.* 2011:109:183-192 Zanotti S, Canalis E. Notch suppresses nuclear factor of activated t cells (nfat) transactivation and 618 47. 619 nfatc1 expression in chondrocytes. *Endocrinology*. 2013;154:762-772 Gunawan F, Gentile A, Gauvrit S, Stainier DYR, Bensimon-Brito A. Nfatc1 promotes interstitial 620 48. cell formation during cardiac valve development in zebrafish. Circulation research. 621 622 2020;126:968-984 623 49. Johnson EN, Lee YM, Sander TL, Rabkin E, Schoen FJ, Kaushal S, Bischoff J. Nfatc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial 624 cells. The Journal of biological chemistry. 2003;278:1686-1692 625 Greenhouse DG, Murphy A, Mignatti P, Zavadil J, Galloway AC, Balsam LB. Mitral valve 626 50. 627 prolapse is associated with altered extracellular matrix gene expression patterns. *Gene*. 628 2016;586:56-61 Prall OW, Menon MK, Solloway MJ, et al. An nkx2-5/bmp2/smad1 negative feedback loop 629 51. 630 controls heart progenitor specification and proliferation. Cell. 2007;128:947-959 631 52. Hulin A, Hortells L, Gomez-Stallons MV, et al. Maturation of heart valve cell populations during 632 postnatal remodeling. Development. 2019;146 633 53. Robson MI, Ringel AR, Mundlos S. Regulatory landscaping: How enhancer-promoter communication is sculpted in 3d. *Molecular cell*. 2019;74:1110-1122 634 635 54. Schoenfelder S, Fraser P. Long-range enhancer-promoter contacts in gene expression control. 636 Nature reviews. Genetics. 2019;20:437-455 Fishilevich S, Nudel R, Rappaport N, et al. Genehancer: Genome-wide integration of enhancers 637 55. 638 and target genes in genecards. Database : the journal of biological databases and curation. 639 2017;2017 640 Xia M, Liu Y, Figueroa DJ, et al. Characterization and localization of a human serine racemase. 56. 641 Brain research. Molecular brain research. 2004;125:96-104 642 57. Soliman H, Paylor B, Scott RW, et al. Pathogenic potential of hic1-expressing cardiac stromal progenitors. Cell stem cell. 2020;26:205-220 e208 643 Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human 644 58. 645 proteome. Science. 2015;347:1260419 Valenta T, Lukas J, Doubravska L, Fafilek B, Korinek V. Hic1 attenuates wnt signaling by 646 59. recruitment of tcf-4 and beta-catenin to the nuclear bodies. The EMBO journal. 2006:25:2326-647 648 2337

- 649 60. Urreizti R, Mayer K, Evrony GD, et al. Dph1 syndrome: Two novel variants and structural and
 650 functional analyses of seven missense variants identified in syndromic patients. *European journal*651 of human genetics : EJHG. 2020;28:64-75
- 65261.McGee MA, Abdel-Rahman AA. N-methyl-d-aspartate receptor signaling and function in
cardiovascular tissues. Journal of cardiovascular pharmacology. 2016;68:97-105

654

Table 1. Potential causal SNPs at the MVP-associated loci. Overlaps with indicated

epigenomic marks are indicated by grey cells. P values were reported for the association with
 MVP obtained in the discovery meta-analysis of GWAS¹² NA: not-available.



Chr	Index SNP	P value	Potential causal SNPs	eQTL genes	Tissue with highest eQTL association	Best eQTL SNP	Risk allele	eQTL p value	Effect size	Topological association
Chr2	rs12465515	3.1×10 ⁻¹¹	3							
Chr3	rs171408	1.3×10 ⁻¹¹	3	LMCD1	Heart - Atrial Appendage	rs165177	С	8x10 ⁻⁷	0.27	Y
				LMCD1-AS1	Pituitary	rs165172	С	$4x10^{-6}$	0.47	Y
Chr14	rs17767392	2.3×10 ⁻⁸	7	SIPA1L1-AS1	Esophagus - Muscularis	rs17767410	С	1×10^{-12}	-0.43	Y
				SIPA1L1	Esophagus - Muscularis	rs17767410	С	6x10 ⁻¹²	-0.27	Y
				PCNX1	Skin - Sun Exposed (Lower leg)	rs7155259	С	1x10 ⁻⁶	0.17	Ν
				RP6-91H8.5	Brain - Cortex	rs7155259	С	1×10^{-5}	0.36	Ν
				COX16	Whole Blood	rs56201715	G	9x10 ⁻⁵	0.1	Ν
Chr17	rs216205	1.5×10 ⁻⁸	20	SRR	Muscle - Skeletal	rs3744270	G	1×10^{-106}	0.8	Y
				TSR1	Skin - Sun Exposed (Lower leg)	rs4477758	Т	$3x10^{-26}$	-0.22	Y
				SGSM2	Skin - Sun Exposed (Lower leg)	rs4477758	Т	6x10 ⁻²⁶	-0.35	Y
				SGSM2-AS1	Skin - Not Sun Exposed (Suprapubic)	rs408067	С	1×10^{-15}	0.25	Y
				HNRNPA1P16	Nerve - Tibial	rs3744270	G	$8x10^{-13}$	-0.34	Ν
				HIC1	Cells - Cultured fibroblasts	rs3744270	G	1×10^{-7}	-0.13	Y
				DPH1	Pancreas	rs9899330	А	$8x10^{-7}$	-0.27	Y
				SMG6	Testis	rs12450028	С	9x10 ⁻⁷	-0.14	Y
				RTN4RL1	Heart - Left Ventricle	rs3815469	G	3x10 ⁻⁵	-0.25	Ν
Chr21	rs62229266	1.2×10 ⁻⁸	4	LINC01436	Artery - Tibial	rs2255858	Т	1×10^{-78}	0.93	Y
				RPL23AP3	Cells - Cultured fibroblasts	rs2255858	Т	$2x10^{-35}$	0.65	Y
				SETD4	Cells - Cultured fibroblasts	rs2255858	Т	$5x10^{-19}$	0.26	Y
				CBR1	Nerve - Tibial	rs2255858	Т	$5 x 10^{-10}$	0.19	Ν
				AP000688.29	Artery - Tibial	rs2255858	Т	8x10 ⁻⁹	0.29	Ν
Chr22	rs11705555	1.4×10 ⁻⁸	7	MN1	Whole Blood	rs73164492	С	3x10 ⁻⁵	-0.21	Y
				TTC28	Muscle - Skeletal	rs11705555	А	6x10 ⁻⁵	-0.15	Ν

Table 2. Potential target genes at MVP-associated loci.

- 661 Candidate SNPs for causality from Table 1 were used at each locus to interrogate potential eQTL association from GTEx v8 database. For each
- eGene identified, the strongest association is reported (strongest tissue, SNP eQTL p-value, and effect size). Effect size sign was adjusted to
- represent the effect of MVP risk allele. P-values are for MVP association reported from the discovery and replication results of each locus.¹² Last
- 664 column indicates whether the TSS of indicated eGenes is located either within 5kb of a potential causal SNP or within 5kb of a fragment that
- 665 interacts topologically with potential causal SNPs, from our 4C-Seq experiments.

666 FIGURE LEGENDS

Figure 1. Quality controls of mitral valve ATAC-Seq experiments.

A: Number of reads (grey) and number of peaks (orange) obtained for mitral valve ATAC-Seq
libraries. B: Spearman correlation and hierarchical clustering of mitral valve ATAC-Seq
datasets. C: Representative read density profile of mitral valve ATAC-Seq datasets on a gene
rich portion of chr1 (11,000,000 to 17,500,000, hg38 coordinates).

672

Figure 2. Comparison of mitral valve, heart, and fibroblast cells ATAC-Seq datasets.

A: Number of reads (grey) and number of peaks (orange) obtained for HDF and HCF ATAC-Seq 674 675 libraries as well as heart tissues: left ventricle (Heart LV) and right atrium auricular region (Heart RAAR) raw reads obtained from ENCODE database. B: Proportion of ATAC-Seq peaks 676 677 located to different genomic regions. C: Spearman correlation and hierarchical clustering of 678 ATAC-Seq datasets from 5 mitral valve samples, 3 fibroblasts samples, and 3 heart tissue samples from left ventricle (Heart LV) or right atrium auricular region (Heart RAAR). D: 679 Principal Component Analysis of 5 mitral valve, 3 fibroblast, and 3 heart ATAC-Seq datasets. 680 Upper panel shows the position of samples with respect to first 2 principal components. Lower 681 682 panel indicates the eigenvalues and explained variance of the first 10 principal components.

683

Figure 3. Analysis of ATAC-Seq identifies mitral valve-specific regulatory elements and pathways.

686 A: Volcano plot representing negative logarithm of enrichment false discovery rate (FDR) on the Y axis and logarithm of enrichment in heart samples over mitral valve samples on the X axis. 687 Each dot represents an ATAC-Seq peak in the mitral valve or heart sample. Pink dots represent 688 689 significantly enriched regions in mitral valve or heart ATAC-Seq experiments (FDR ≤ 0.05). B-C: 690 Bubble graphs represent GOBP terms enriched among genes at proximity (distance to 691 TSS ≤ 10 kb) of heart- (**B**) and mitral valve- (**C**) specific peaks. X and Y axes are in arbitrary semantic coordinates.²⁵ Bubble size represents number of semantically similar terms aggregated 692 under the same index GO term. Bubble color represents the p-value of GO term enrichment for 693

the index GO term. **D-E**: Motif sequence and logo of most enriched motifs in heart- (**D**) and mitral valve- (**E**) specific peaks. Motifs were detected *de novo* using DREME algorithm. Top 3 motifs are represented. E-val indicates the erased expected value (E-value) calculated by DREME. "Transcription factors" indicate the top transcription factor or transcription factor family detected by TOMTOM algorithm as possible factors binding the detected motif. "Central enrichment" represents the enrichment of motifs with respect to ATAC-Seq peak summits.

700

Figure 4. rs6723013 is a potential causal variant at the *IGFBP5/TNS1* MVP-associated locus.

703 A: Representation of MVP SNPs fold-enrichment (X-axis) and enrichment p-value (log scale, Y-704 axis) among indicated ATAC-Seq samples. MVP SNPs overlap with ATAC-Seq peaks was 705 compared to 500 pools of randomized matched SNPs to calculate the indicated enrichments. B: 706 Luciferase reporter gene assay comparing the regulatory activity of constructs containing 707 rs6723013-region (T and G alleles) and a control region. The p-value of a student's t-test comparing luciferase values of rs6723013 alleles is indicated. C-D: Conditional analysis at 708 709 *IGFBP5/TNS1* locus. LocusZoom plots represent MVP association before (C) and after (D) conditioning on rs6723013. 710

711

712 Figure 5. 4C-Seq analysis of the *SMG6/SRR* MVP-associated locus.

Interacting fragment density profiles from SNP rs2641440, rs9898819, rs2281727, and rs9899330 viewpoints using 4C-Seq. Fragments in significant interaction with the viewpoint are indicated by black bars under the interaction plot. Genomic coordinates, GRCh38.





Fig 2

















Fig S1

С

-value)

-d)0160

Ε





100 8

80

60

40

(OMA)

PAFAH1B1→

+RTN4RL1

.....

DPH1→

OVCA2→

← MIR132

← MIR212

HIC1→

2

Position on chr17 (Mb)

<--SMG6

LOC101927839-+

SGSM2→

SRR→

← TSR1

- SNORD91B

- SNORD91A

2.2

- MNT

←LOC284009

← METTL16

2.4

- SMYD4

RPA1→

1.8

Fig S2







Distance (bp) relative to the viewpoint



Distance (bp) relative to the viewpoint

Fig S3 A





Fig S4



Distance (bp) relative to the viewpoint

Fig S5



B R

150000

50000

0

Reads

ction Fragments

q-value g-value<=0.00001 0.0001 >q-value<= 0.001 0.001 >q-value<= 0.01 0.01 >q-value<= 0.01 0.01 >q-value<= 0.05 0.05 >q-value<= 0.1

value<= 0.2

-4e+05

-2e+05



nw.

2e+05

0e+00

Distance (bp) relative to the viewpoint

4e+05





Lallann